Interet clinique de l'immunoscintigraphie avec le fragment d'anticorps Fab'-Immu-4 marque au 99mTc avant reintervention chirurgicale dans le cancer du colon ou du rectum

Translated title of the contribution: Clinical utility of immunoscintigraphy with the Immu-4 99mTc-Fab' antibody fragment in patients undergoing surgery for carcinoma of the colon and rectum

Frederick L Moffat, C. M. Pinsky, L. Hammershaimb, N. J. Petrelli, Y. Z. Patt, F. S. Whaley, D. M. Goldenberg

Research output: Contribution to journalArticle

Abstract

The purpose of these prospective, pivotal studies was to assess the performance and the potential clinical impact of a new antibody imaging agent, CEA-Scan(TM), in 210 presurgical patients with advanced recurrent or metastatic colorectal carcinomas. CEA-Scan(TM), an anti-carcinoembryonic antigen (CEA) Fab' antibody fragment labeled with 99mTc, was injected IV and external scintigraphy performed 2-5 h and 18-24 h later. Imaging with conventional diagnostic modalities (CDM) was also performed, and findings were confirmed by surgery and histology. The sensitivity of CEA-Scan(TM) was superior to that of CDM in the extrahepatic abdomen (55% vs 32%, p = 0,007) and pelvis (69% vs 48%, p = 0,005), and CEA-Scan(TM) findings complemented those of CDM in the liver. Among 122 patients with known disease, the positive predictive value was significantly higher when both modalities were positive (98%) as compared to each alone (68%-70%), potentially obviating the need for histological confirmation when both tests are positive. Imaging accuracy also was significantly improved by adding CEA-Scan(TM) to CDM. In 88 patients with occult cancer, imaging accuracy was enhanced significantly by CEA-Scan(TM) combined with CDM (61% vs 33%). Potential clinical benefit from CEA-Scan(TM) was demonstrated in 89 of 210 patients. Only two patients developed human antimouse antibodies (HAMA) to CEA-Scan(TM) after a single injection, and none of 19 assessable patients after two injections.

Original languageFrench
Pages (from-to)275-283
Number of pages9
JournalMedecine Nucleaire
Volume20
Issue number4-5
StatePublished - Jan 1 1996

Fingerprint

Immunoglobulin Fragments
Immunoglobulin Fab Fragments
Carcinoembryonic Antigen
Rectum
Colon
Carcinoma
Injections
Antibodies
Pelvis
Radionuclide Imaging
Abdomen
Colorectal Neoplasms
Histology
Prospective Studies
Liver

Keywords

  • Tc-anti-CEA antibody
  • colon-cancer
  • CT-scan
  • immunoscintigraphy
  • surgery

ASJC Scopus subject areas

  • Biophysics
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Cite this

Interet clinique de l'immunoscintigraphie avec le fragment d'anticorps Fab'-Immu-4 marque au 99mTc avant reintervention chirurgicale dans le cancer du colon ou du rectum. / Moffat, Frederick L; Pinsky, C. M.; Hammershaimb, L.; Petrelli, N. J.; Patt, Y. Z.; Whaley, F. S.; Goldenberg, D. M.

In: Medecine Nucleaire, Vol. 20, No. 4-5, 01.01.1996, p. 275-283.

Research output: Contribution to journalArticle

Moffat, Frederick L ; Pinsky, C. M. ; Hammershaimb, L. ; Petrelli, N. J. ; Patt, Y. Z. ; Whaley, F. S. ; Goldenberg, D. M. / Interet clinique de l'immunoscintigraphie avec le fragment d'anticorps Fab'-Immu-4 marque au 99mTc avant reintervention chirurgicale dans le cancer du colon ou du rectum. In: Medecine Nucleaire. 1996 ; Vol. 20, No. 4-5. pp. 275-283.
@article{2e940ba2da71420c924e58944382bb16,
title = "Interet clinique de l'immunoscintigraphie avec le fragment d'anticorps Fab'-Immu-4 marque au 99mTc avant reintervention chirurgicale dans le cancer du colon ou du rectum",
abstract = "The purpose of these prospective, pivotal studies was to assess the performance and the potential clinical impact of a new antibody imaging agent, CEA-Scan(TM), in 210 presurgical patients with advanced recurrent or metastatic colorectal carcinomas. CEA-Scan(TM), an anti-carcinoembryonic antigen (CEA) Fab' antibody fragment labeled with 99mTc, was injected IV and external scintigraphy performed 2-5 h and 18-24 h later. Imaging with conventional diagnostic modalities (CDM) was also performed, and findings were confirmed by surgery and histology. The sensitivity of CEA-Scan(TM) was superior to that of CDM in the extrahepatic abdomen (55{\%} vs 32{\%}, p = 0,007) and pelvis (69{\%} vs 48{\%}, p = 0,005), and CEA-Scan(TM) findings complemented those of CDM in the liver. Among 122 patients with known disease, the positive predictive value was significantly higher when both modalities were positive (98{\%}) as compared to each alone (68{\%}-70{\%}), potentially obviating the need for histological confirmation when both tests are positive. Imaging accuracy also was significantly improved by adding CEA-Scan(TM) to CDM. In 88 patients with occult cancer, imaging accuracy was enhanced significantly by CEA-Scan(TM) combined with CDM (61{\%} vs 33{\%}). Potential clinical benefit from CEA-Scan(TM) was demonstrated in 89 of 210 patients. Only two patients developed human antimouse antibodies (HAMA) to CEA-Scan(TM) after a single injection, and none of 19 assessable patients after two injections.",
keywords = "Tc-anti-CEA antibody, colon-cancer, CT-scan, immunoscintigraphy, surgery",
author = "Moffat, {Frederick L} and Pinsky, {C. M.} and L. Hammershaimb and Petrelli, {N. J.} and Patt, {Y. Z.} and Whaley, {F. S.} and Goldenberg, {D. M.}",
year = "1996",
month = "1",
day = "1",
language = "French",
volume = "20",
pages = "275--283",
journal = "Medecine Nucleaire",
issn = "0928-1258",
publisher = "Elsevier Masson",
number = "4-5",

}

TY - JOUR

T1 - Interet clinique de l'immunoscintigraphie avec le fragment d'anticorps Fab'-Immu-4 marque au 99mTc avant reintervention chirurgicale dans le cancer du colon ou du rectum

AU - Moffat, Frederick L

AU - Pinsky, C. M.

AU - Hammershaimb, L.

AU - Petrelli, N. J.

AU - Patt, Y. Z.

AU - Whaley, F. S.

AU - Goldenberg, D. M.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - The purpose of these prospective, pivotal studies was to assess the performance and the potential clinical impact of a new antibody imaging agent, CEA-Scan(TM), in 210 presurgical patients with advanced recurrent or metastatic colorectal carcinomas. CEA-Scan(TM), an anti-carcinoembryonic antigen (CEA) Fab' antibody fragment labeled with 99mTc, was injected IV and external scintigraphy performed 2-5 h and 18-24 h later. Imaging with conventional diagnostic modalities (CDM) was also performed, and findings were confirmed by surgery and histology. The sensitivity of CEA-Scan(TM) was superior to that of CDM in the extrahepatic abdomen (55% vs 32%, p = 0,007) and pelvis (69% vs 48%, p = 0,005), and CEA-Scan(TM) findings complemented those of CDM in the liver. Among 122 patients with known disease, the positive predictive value was significantly higher when both modalities were positive (98%) as compared to each alone (68%-70%), potentially obviating the need for histological confirmation when both tests are positive. Imaging accuracy also was significantly improved by adding CEA-Scan(TM) to CDM. In 88 patients with occult cancer, imaging accuracy was enhanced significantly by CEA-Scan(TM) combined with CDM (61% vs 33%). Potential clinical benefit from CEA-Scan(TM) was demonstrated in 89 of 210 patients. Only two patients developed human antimouse antibodies (HAMA) to CEA-Scan(TM) after a single injection, and none of 19 assessable patients after two injections.

AB - The purpose of these prospective, pivotal studies was to assess the performance and the potential clinical impact of a new antibody imaging agent, CEA-Scan(TM), in 210 presurgical patients with advanced recurrent or metastatic colorectal carcinomas. CEA-Scan(TM), an anti-carcinoembryonic antigen (CEA) Fab' antibody fragment labeled with 99mTc, was injected IV and external scintigraphy performed 2-5 h and 18-24 h later. Imaging with conventional diagnostic modalities (CDM) was also performed, and findings were confirmed by surgery and histology. The sensitivity of CEA-Scan(TM) was superior to that of CDM in the extrahepatic abdomen (55% vs 32%, p = 0,007) and pelvis (69% vs 48%, p = 0,005), and CEA-Scan(TM) findings complemented those of CDM in the liver. Among 122 patients with known disease, the positive predictive value was significantly higher when both modalities were positive (98%) as compared to each alone (68%-70%), potentially obviating the need for histological confirmation when both tests are positive. Imaging accuracy also was significantly improved by adding CEA-Scan(TM) to CDM. In 88 patients with occult cancer, imaging accuracy was enhanced significantly by CEA-Scan(TM) combined with CDM (61% vs 33%). Potential clinical benefit from CEA-Scan(TM) was demonstrated in 89 of 210 patients. Only two patients developed human antimouse antibodies (HAMA) to CEA-Scan(TM) after a single injection, and none of 19 assessable patients after two injections.

KW - Tc-anti-CEA antibody

KW - colon-cancer

KW - CT-scan

KW - immunoscintigraphy

KW - surgery

UR - http://www.scopus.com/inward/record.url?scp=0029852051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029852051&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0029852051

VL - 20

SP - 275

EP - 283

JO - Medecine Nucleaire

JF - Medecine Nucleaire

SN - 0928-1258

IS - 4-5

ER -